EUCTR2014-002061-30-GB进行中（未招募）1 期
Therapeutic HPV vaccine trial +/- anti-CD40 in HPV-driven squamous cell carcinoma. - HARE-40
niversity Hospital Southampton NHS Foundation Trust0 个研究点目标入组 153 人开始时间: 2016年3月17日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 153
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Previous HPV16+ head and neck squamous cell carcinoma.
- •At least 12 months after completion of treatment.
- •Within 5 years of treatment completion.
- •Currently no clinical evidence of disease.
- •ECOG performance status 0 or 1.
- •Able to provide written informed consent.
- •HPV16+ head and neck, cervical, anogenital and penile carcinoma patients with recurrent disease.
- •Intention to treat is palliative.
- •Patient willing to have repeated tumour biopsies and re-biopsy deemed safe and feasible clinically.
- •Tissue samples available confirming HPV16+ disease to send to Central Laboratory.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 123
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •Arm 1A and 1B:
- •Patients unable to consent.
- •Any patient who has been previously vaccinated in any Arm of the trial.
- •<18 years
- •Systemic steroids (prednisolone >10 mg/day or equivalent) or other drugs with a likely effect on immune competence are forbidden during the trial. The predictable need of their use will preclude the patient from trial entry. Replacement steroids for adrenal insufficiency/failure are allowed.
- •Major surgery in the preceding three to four weeks, which the patient has not yet recovered from.
- •Patients who are of high medical risk because of non-malignant systemic disease, as well as those with active uncontrolled infection.
- •Patients with clinically relevant autoimmune disease will be excluded.
- •Patient with a history of anaphylactic reactions or severe allergies are excluded.
- •Patients with any other condition which in the Investigator’s opinion would not make the patient a good candidate for the clinical trial, such as concurrent congestive heart failure or prior history of New York Heart Association (NYHA) class III/IV cardiac disease.
- •Current malignancies at other sites, with the exception of adequately treated basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for five years and are deemed at low risk for recurrence, are eligible for the study.
- •Patients who are serologically positive for or are known to suffer from Hepatitis B, C, Syphilis or HIV. Counselling will be offered to all patients prior to testing.
- •Patients who have a positive pregnancy test or who are breast feeding.
- •Fertile males or females who are unable or unwilling to use an effective method of birth control (eg. condom with spermicide, diaphragm with spermicide, birth control pills, injections, patches, intrauterine device, or intrauterine hormone-releasing system) during study treatment and until 28 days after patients finish the study end of treatment.
- •Elevated Liver Function Tests – ALT >3.0 x ULN, AST >3.0 x ULN, Bilirubin >3.0 x ULN.
- •Any other investigational drug within 28 days or 5 half-lives depending on what gives the longer range before the first treatment of this study
研究者
相似试验
已完成
不适用
Therapeutic HPV vaccine trial +/- anti-CD40 in HPV-driven squamous cell carcinomaHPV-driven squamous cell carcinomaCancerISRCTN51789191niversity Hospital Southampton NHS Foundation Trust15
已完成
不适用
The Canadian Cervical Cancer Screening Trial of human papillomavirus (HPV) testing versus Pap cytologyCancerISRCTN57612064McGill University (Canada) - Research Grants Office10,154
进行中（未招募）
1 期
Vaccination against human papillomavirus (HPV) after allogeneic stem cell transplantation, a randomized study between early and late vaccination.Recipients of allogeneic stem cell transplantationCTIS2022-502912-35-00Vastra Gotalandsregionen100
已完成
4 期
Quadrivalent HPV vaccination after effective treatment of Anal Intraepithelial Neoplasia in HIV+ men (VACCAIN-P)anal intraepithelial neoplasia1004743810017987NL-OMON44810Academisch Medisch Centrum125
进行中（未招募）
1 期
HPV vaccination after treatment of anal intraepithelial neoplasiaIntra-anal high-grade anal intraepithelial neoplasia (AIN) (grade 2-3) in HIV+ men that was successfully treated in the past year with conventional cauterization, cryotherapy, or other forms of local treatment.MedDRA version: 14.1 Level: LLT Classification code 10059312 Term: Anal dysplasia System Organ Class: 100000004856EUCTR2013-002009-70-NLAcademic Medical Center125